Adults with atypical hemolytic uremic syndrome (aHUS) in the U.K. who didn’t receive treatment with Soliris (eculizumab) had a 43% chance of developing end-stage kidney disease within five years, according to a study that found this severe form of kidney damage was less likely in children within the…
News
Soliris (eculizumab) helped ease disease symptoms for a woman with multiple myeloma who developed atypical hemolytic uremic syndrome (aHUS) as a complication of a viral infection caused by H1N1 influenza — also known as influenza A, or swine flu. “The prompt recognition and initiation of anti-complement therapy played…
Most people with atypical hemolytic uremic syndrome (aHUS) who are stable on Soliris (eculizumab) can stop treatment after at least six months without having a relapse, provided that they’re carefully monitored, a recent study reported. Scientists expect that this could prevent treatment-related complications and burden for patients, while…
Atypical hemolytic uremic syndrome (aHUS) can occur as a rare complication of surgery involving the urinary tract, according to a report from Italy detailing the case of a woman in her 40s who developed the condition after undergoing a procedure to remove kidney stones. The patient, who had a…
A 38-year-old woman who developed pregnancy-associated atypical hemolytic uremic syndrome (P-aHUS) after giving birth via cesarean section successfully recovered following treatment with Soliris (eculizumab), a case report from China shows. Genetic testing revealed the presence of a mutation in the CFH gene, which likely contributed to her condition.
Short-term use of Soliris (eculizumab) in India — where the drug was approved just this year for treating two rare diseases — was effective for five children with atypical hemolytic uremic syndrome (aHUS), according to a new report. While the antibody therapy has been approved as an aHUS…
Adults with atypical hemolytic uremic syndrome (aHUS) who start Soliris (eculizumab) within seven days after their symptoms start see the best outcomes, a small real-world study in Western China suggests. The patients showed significantly improved blood and kidney function, and a reduced need for dialysis, while most given…
Atypical hemolytic uremic syndrome (aHUS) can occur concurrently with disseminated intravascular coagulation (DIC), a blood disorder marked by similar symptoms, but that has different underlying causes. The case of a boy with both aHUS and DIC was highlighted in the paper, “A Case Report of Atypical…
A 29-year-old woman in the U.S. showed signs of atypical hemolytic uremic syndrome (aHUS) and a C2 gene mutation, but without infection caused by Shiga toxin-producing Escherichia coli (STEC), according to a case report. STEC bacteria are the cause of the typical form of the disease. Genetic testing could…
Switching from Soliris (eculizumab) to Ultomiris (ravulizumab) is a safe and effective treatment strategy for people with atypical hemolytic uremic syndrome (aHUS), according to a real-world study in Japan. The treatment switch was associated with stable levels of blood and kidney-related disease markers, preventing disease relapse or…
Recent Posts
- How aHUS treatment led to my first tattoos
- Ultomiris at lower doses just as safe, effective for children with aHUS: Study
- Strange symptoms make me wonder if I’m having neurological complications
- Leaky artificial heart valve triggers rare aHUS in woman, 70: Report
- How my body naturally reacts to one of my bad habits
- Study finds alternative pathway is main driver of aHUS
- Rapid, sustained aHUS response seen with Ultomiris in real-world data
- Team care saves mother with trio of postpartum complications
- Once a good side hustle, donating plasma is now too risky for me
- Treatment halts aHUS recurrence after COVID-triggered relapse